Malaysian Pharmacovigilance Guidelines 2nd Edition

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive

Second Edition

  • The Malaysian Guidelines for the Reporting & Monitoring 2002 has been updated to align with current international requirements in adverse drug reaction (ADR) reporting and safety monitoring for medicinal products.
  • In addition, this guideline has been updated to explain in detail on ADR reporting for Healthcare Professionals and Product Registration Holders.
  • This guideline will be implemented with immediate effect.

(Refer letter to Product Registration Holders, Ruj.Kami: (73)dlm.BPFK/17/FV/4 JILID51, Date: 5 September 2016)



Comments (0)

There are no comments posted here yet

Leave your comments

Posting comment as a guest.
0 Characters
Attachments (0 / 3)
Share Your Location

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language